Mobia Medical's $150M IPO Met with Tepid Wall Street Debut

AUSTIN, TX – May 08, 2026 – Mobia Medical, Inc., a company aiming to redefine stroke recovery, made its public market debut on the Nasdaq today, raising approximately $150 million in its Initial Public Offering. However, the milestone was tempered by a cool reception from investors, as the company’s stock saw a significant drop in its first day of trading.

The Austin-based firm priced its 10 million shares at $15.00 each, the midpoint of its expected range. Trading under the ticker symbol “MOBI,” the stock closed its inaugural session at $11.75, a decline of 21.7%. The offering, which is expected to close on May 11, 2026, was led by a consortium of high-profile underwriters, including BofA Securities, J.P. Morgan, and Goldman Sachs & Co. LLC.

The IPO provides a critical infusion of capital for the commercial-stage company, but the first-day performance highlights the challenging environment for new medtech listings, even for companies with promising, FDA-approved technology.

A New Lifeline for Stroke Recovery

At the heart of Mobia Medical's mission is the Vivistim® Paired VNS™ System, an innovative implantable device designed to help survivors of chronic ischemic stroke regain upper limb function. The company, which operated as MicroTransponder, Inc. until a name change in February 2026, has developed a system that pairs targeted vagus nerve stimulation (VNS) with intensive physical therapy.

The therapy works by stimulating the vagus nerve—a major communication pathway between the body and the brain—at the precise moment a patient attempts a specific movement. This pairing is believed to enhance neuroplasticity, the brain's ability to rewire itself, thereby accelerating and improving motor function recovery long after a stroke has occurred. This approach marks a significant departure from traditional rehabilitation, which often yields limited results for patients with chronic impairments.

The Vivistim system earned a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) and received full FDA approval in August 2021. It stands as the first and only clinically validated, implantable solution approved for improving upper limb function in this specific patient population. Clinical data has been compelling; the pivotal VNS-REHAB study, published in The Lancet, showed patients using Vivistim therapy achieved two to three times greater improvement in motor function compared to those who received intense rehabilitation alone. Follow-up data published in the journal Stroke in May 2025 confirmed that these functional gains were maintained for at least one year after therapy.

Fueling Expansion Amid Financial Headwinds

Despite its clinical promise, Mobia Medical has operated at a significant loss since its inception in 2007. While revenues surged 104.8% to $32.0 million in fiscal year 2025, the company reported a net loss of $46.5 million for the same period, up from a $24.6 million loss in 2024. The proceeds from the IPO are therefore essential to sustaining and scaling operations.

According to its filings, Mobia plans to use approximately $93.5 million of the net proceeds to aggressively expand its commercial footprint. This includes growing its direct sales force and market development teams to broaden awareness among physicians, rehabilitation centers, and patients. The company has already seen growing adoption since its commercial launch in 2023, with over 1,000 Vivistim systems implanted to date, 700 of which occurred in 2025 alone.

However, a significant hurdle remains in securing consistent reimbursement. The Vivistim system’s transitional pass-through payment status from the Centers for Medicare and Medicaid Services (CMS) expired at the end of 2025. While CMS has assigned a new payment classification for 2026, the company notes in its filings that many private commercial payers still consider the therapy experimental or investigational. This has led to coverage denials and lengthy prior authorization processes, creating a barrier to patient access that the expanded commercial team will need to navigate.

A Unique Approach in a Competitive Landscape

Mobia Medical estimates it is targeting a vast and underserved market. Of the more than four million chronic ischemic stroke survivors in the United States, the company believes over one million are suitable candidates for its therapy, representing a potential market opportunity of $30 billion.

While the Vivistim system is unique as an implantable VNS solution for stroke, it enters a broader neurorehabilitation market that is rapidly evolving. The field is seeing increased adoption of technologies like robotic exoskeletons, AI-driven feedback systems, and other forms of neurostimulation, such as transcranial direct current stimulation (tDCS). Furthermore, the VNS field itself is trending towards non-invasive, wearable devices for a range of other conditions, which could influence long-term market dynamics and patient preferences.

Mobia's strategy relies on its strong clinical evidence and its first-mover advantage as the only FDA-approved device of its kind. The company is betting that the significant and lasting improvements demonstrated in its trials will establish Vivistim as a new standard of care for a patient group with few effective options.

Experienced Leadership at the Helm

Guiding Mobia Medical through its transition to a public company is a leadership team with deep experience in the medical device industry. President and CEO Richard Foust, who joined in 2022, has over two decades of experience, including senior commercial roles at Abbott. The board is chaired by Dana G. Mead, Jr., a veteran healthcare executive who previously led HeartFlow and serves on the boards of established public companies like Inspire Medical and Pulmonx.

This seasoned leadership will be crucial as Mobia Medical navigates the pressures of the public market, manages its cash burn, and works to overcome reimbursement hurdles. With fresh capital and a clinically validated product, the company is poised to expand its reach, but its success will ultimately depend on its ability to convince both the medical community and Wall Street of its long-term value.